Viewing Study NCT04173494

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:44 AM
Ignite Modification Date: 2026-03-02 @ 4:23 PM
Study NCT ID: NCT04173494
Status: COMPLETED
Last Update Posted: 2023-11-01
First Post: 2019-11-20
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Sponsor: Sierra Oncology LLC - a GSK company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Myelofibrosis View
None Post-polycythemia Vera Myelofibrosis View
None Post-essential Thrombocythemia Myelofibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelofibrosis View
None JAK inhibitor View
None Danazol View
None Momelotinib View
None Functional Iron deficiency View
None Activin receptor type 1 View
None Anemia View
None Transfusion View
None Hepcidin View
None Myeloproliferative Disorders View
None Bone Marrow Diseases View
None Hematologic Diseases View